Standards, options and recommendations: Concomitant radiochemotherapy for cancer of the cervix: A critical analysis of the literature and update of SOR;Radiochimiotherapie concomitante dans les cancers du col de l'uterus: Analyse critique des donnees et mise a jour des Standards, Options et Recommandations

Cancer/Radiotherapie

Volumn 4, Issue 1, 2000, Pages 60-75

  Haie Meder, C ^a   Fervers, B ^b   Chauvergne, J ^c   Fondrinier, E ^d   Lhomme C ^a   Bataillard, A ^b   Guastalla, J P ^e   Resbeut, M ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b FNCLCC   (France)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE PAUL PAPIN   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT PAOLI CALMETTES   (France)

Author keywords

Adult; Cancer; Carcinoma of the cervix; Chemotherapy; Concomitant radiochemotherapy; Neoplasms; Radiotherapy; Recommendations for clinical practice

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; HYDROXYUREA;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH CARE QUALITY; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RISK FACTOR; UTERINE CERVIX CANCER; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; PRACTICE GUIDELINE; UTERINE CERVIX TUMOR;

COMBINED MODALITY THERAPY; DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; UTERINE CERVICAL NEOPLASMS;

EID: 0034108189     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(00)88653-9     Document Type: Article

References (25)

1. Barillot I, Horiot JC, Pigneux J, Schraub S, Rozan R, et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: A french cooperative study: Update and multivariate analysis of pronostic factors. Int J Radiat Oncol Biol Phys 1997; 58: 969-78.
2. Choo YC, Choy TK, Wong LC, Ma HK. Potentiation of radiotherapy by cis-dichlorodiammine platinum (II) in advanced cervical carcinoma. Gynecol Oncol 1986; 23: 94-100.
3. Fervers B, Bonichon F, Demard F, Heron JF, Mathoulin S, Philip T, Méthodologie de développement des standard, options et recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995; 82: 761-7.
4. Girinsky T, Rey A, Roche B. Haie C, Gerbaulet A, Randrianarivello H, et al. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993; 27: 1051-6.
5. Horiot JC, Pigneux J, Pourquier H, Schraub S, Achille E, Keiling R, Radiotherapy alone in carcinoma of the intact uerine cervix according to G.H. Fletcher guidelines: A French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys 1988; 14: 605-11.
6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma [see comments]. N Engl J Med 1999; 340: 1154-61.
7. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage lb-iia cervical cancer [see comments]. Lancet 1997; 350 (9077): 535-40.
8. Malfetano J, Keys H, Kredentser D, Cunningham M, Kotlove D, Weiss L. Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer 1993; 71: 3703-6.
9. Monaghan J. Time to add chemotherapy to radiotherapy for cervical cancer. Lancet 1999; 353: 1288-9.
10. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer [see comments], N Engl J Med 1999; 340: 1137-43.
11. NIH. National Institute of Health. Consensus development conference. Cervical Cancer. April 1-3, 1996. Consens Statement 1996; 14: 1-38.
12. Perez CA, Fox S, Lockett MA, Grigsby PW, Camel HM, Galakatos A, et al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: Analysis of two different methods. Int J Radiat Oncol Biol Phys 1991; 21: 885-98.
13. Perez CA, Grigsby PW, Chao KS, Mutch DG, Lockett MA. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 1998; 41: 307-17.
14. Peters WA, Liu PY, Barrett R, Gordon W, Stock R, Berek JF, et al. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III inter-group study. 30th Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, USA, March 20-24, 1999.
15. Resbeut M, Cowen D, Viens P, Noirclerc M, Perez T, Gouvernet J, Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. Gynecol Oncol 1994; 54: 68-75.
16. Resbeut M, Fondrinier E, Fervers B, Asselain B, Basuyau JP, Brémond A, et al. Fédération nationale des centres de lutte contre le cancer. Société française d'oncologie gynécologique. Standard, options et recommandations. Cancers Invasifs du col Utérin (Stades non Métastatiques). Paris: John Libbey Eurotext, 1999; vol 9.
17. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer [see comments]. N Engl J Med 1999; 340: 1144-53.
18. Secrétariat d'État à la Santé. Ministère de L'emploi et de la Solidarité, ed. Le Cancer en France: Incidence et Mortalité. Situation en 1995, Évolution Entre 1975 et 1995. Réseau Francim rev. ed.; 1998.
19. Stehman FB, Bundy BN, Kucera PR, Deppe G, Reddy S, O'Connor DM. Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: A phase I-II trial of the gynecologic oncology group. Gynecol Oncol 1997; 66: 262-7.
20. Thomas G, Dembo A, Ackerman I, Franssen E, Balogh J, Fyles A, A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol 1998; 69: 137-45.
21. Thomas GM. Improved treatment for cervical cancer - Concurrent chemotherapy and radiotherapy [editorial; comment]. N Engl J Med 1999; 340: 1198-200.
22. Tseng CJ, Chang CT, Lai CH, Soong YK, Hong JH, Tang SG, et al. A randomized trial of concurrent chemoradiotherapy versus radio-therapy in advanced carcinoma of the uterine cervix. Gynecol Oncol 1997; 66: 52-8.
23. Whitney CW, Sause W, Bundy BN, Maletano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339-48.
24. Wong LC, Choo YC, Choy D, Sham JS, Ma HK. Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol Oncol 1989; 35: 159-63.
25. Wong LC, Ngan HYS, Cheung ANY, Cheng DKL, Choy DTK. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999; 17: 2055-60.